Jane Street’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.8M Sell
77,362
-12,385
-14% -$2.75M ﹤0.01% 1952
2025
Q4
$20.5M Sell
89,747
-203,232
-69% -$46.3M ﹤0.01% 1606
2025
Q3
$67.8M Sell
292,979
-283,225
-49% -$57.7M 0.01% 787
2025
Q2
$107M Buy
576,204
+562,642
+4,149% +$105M 0.02% 440
2025
Q1
$2.84M Sell
13,562
-249,563
-95% -$48.5M ﹤0.01% 3795
2024
Q4
$46.8M Buy
263,125
+102,673
+64% +$18.9M 0.01% 725
2024
Q3
$31.7M Sell
160,452
-297,912
-65% -$55.6M 0.01% 942
2024
Q2
$78.6M Buy
458,364
+130,416
+40% +$21.6M 0.02% 487
2024
Q1
$59.7M Sell
327,948
-9,673
-3% -$1.67M 0.01% 546
2023
Q4
$52.3M Sell
337,621
-204,836
-38% -$29.9M 0.01% 650
2023
Q3
$80.9M Buy
542,457
+232,598
+75% +$34.1M 0.03% 393
2023
Q2
$41.7M Buy
309,859
+150,289
+94% +$22M 0.01% 693
2023
Q1
$25.4M Sell
159,570
-171,068
-52% -$26.2M 0.01% 849
2022
Q4
$53.4M Buy
330,638
+4,589
+1% +$704K 0.02% 499
2022
Q3
$43.8M Buy
326,049
+2,652
+0.8% +$381K 0.02% 575
2022
Q2
$49.5M Buy
323,397
+156,016
+93% +$23.8M 0.02% 566
2022
Q1
$27.1M Sell
167,381
-190,574
-53% -$27.7M 0.01% 1036
2021
Q4
$48.5M Sell
357,955
-56,970
-14% -$6.73M 0.02% 670
2021
Q3
$44.8M Sell
414,925
-23,262
-5% -$2.66M 0.02% 648
2021
Q2
$49.4M Buy
438,187
+1,621
+0.4% +$183K 0.02% 557
2021
Q1
$47.2M Buy
436,566
+186,886
+75% +$20M 0.02% 498
2020
Q4
$26.8M Buy
249,680
+204,342
+451% +$19.6M 0.01% 703
2020
Q3
$3.97M Sell
45,338
-24,044
-35% -$2.26M ﹤0.01% 2117
2020
Q2
$6.81M Buy
69,382
+37,686
+119% +$3.32M 0.01% 1509
2020
Q1
$2.42M Sell
31,696
-84,813
-73% -$7.22M ﹤0.01% 1829
2019
Q4
$10.3M Sell
116,509
-44,421
-28% -$3.69M 0.01% 626
2019
Q3
$12.2M Sell
160,930
-252,980
-61% -$17.3M 0.02% 512
2019
Q2
$30.1M Buy
413,910
+282,326
+215% +$22.2M 0.05% 270
2019
Q1
$10.6M Buy
131,584
+107,805
+453% +$8.82M 0.02% 651
2018
Q4
$2.19M Sell
23,779
-46,832
-66% -$4.12M ﹤0.01% 1629
2018
Q3
$6.68M Sell
70,611
-104,218
-60% -$9.88M 0.01% 849
2018
Q2
$16.2M Buy
174,829
+105,637
+153% +$10.3M 0.04% 386
2018
Q1
$6.55M Sell
69,192
-287,779
-81% -$31.6M 0.02% 785
2017
Q4
$34.5M Buy
356,971
+281,060
+370% +$26.5M 0.1% 175
2017
Q3
$6.75M Sell
75,911
-23,682
-24% -$1.8M 0.02% 690
2017
Q2
$7.22M Buy
99,593
+42,733
+75% +$2.87M 0.03% 600
2017
Q1
$3.71M Buy
56,860
+48,287
+563% +$3.04M 0.02% 898
2016
Q4
$537K Sell
8,573
-41,537
-83% -$2.54M ﹤0.01% 2786
2016
Q3
$3.16M Buy
50,110
+29,080
+138% +$1.88M 0.02% 837
2016
Q2
$1.3M Buy
+21,030
New +$1.28M 0.01% 1703
2016
Q1
Sell
-6,235
Closed -$348K 3999
2015
Q4
$369K Buy
+6,235
New +$359K ﹤0.01% 2834
2015
Q3
Sell
-54,763
Closed -$3.56M 3492
2015
Q2
$3.68M Sell
54,763
-53,257
-49% -$3.48M 0.02% 622
2015
Q1
$6.32M Buy
108,020
+101,479
+1,551% +$6.13M 0.05% 315
2014
Q4
$428K Buy
6,541
+2,084
+47% +$131K ﹤0.01% 1609
2014
Q3
$257K Sell
4,457
-14,835
-77% -$824K ﹤0.01% 2001
2014
Q2
$1.09M Buy
+19,292
New +$1.01M 0.01% 856
2014
Q1
Sell
-29,286
Closed -$1.55M 2634
2013
Q4
$1.55M Sell
29,286
-67,405
-70% -$3.31M 0.02% 574
2013
Q3
$4.33M Sell
96,691
-18,804
-16% -$834K 0.05% 274
2013
Q2
$4.78M Buy
+115,495
New +$5.05M 0.08% 181

Other funds holding ABBV

Jane Street's ABBV Position: Q1 2026 in Review

Jane Street reduced its AbbVie (ABBV) stake by 14% in Q1 2026, selling an estimated $2.75M and leaving 77,362 shares worth $16.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

Jane Street first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $107M in Q2 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Jane Street held 77,362 shares of AbbVie worth $16.8M as of Q1 2026.
  • Jane Street sold 12,385 AbbVie shares in Q1 2026, an estimated $2.75M.
  • AbbVie made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #1952 holding.
  • Jane Street first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
  • Jane Street's AbbVie position peaked at $107M in Q2 2025.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.